Furthermore, LIF nAbs used with gemcitabine significantly reduced the growth of patient-derived xenograft (PDX) tumors in vivo. These results are in stark contrast to earlier findings in breast cancer demonstrating that LIF-LIFR signaling activated the Hippo pathway, thereby inhibiting YAP and TAZ. This evidence concerns the gene WWTR1 and breast carcinoma.